



## **Tactile Medical to Release Third Quarter of Fiscal Year 2019 Financial Results on November 4, 2019**

September 30, 2019

MINNEAPOLIS, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that third quarter of fiscal year 2019 financial results will be released after the market closes on Monday, November 4.

Management will host a conference call at 5:00 p.m. Eastern Time on November 4 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 833-286-5804 (647-689-4449 for international callers) and provide access code 9563758. A live webcast of the call will also be provided on the investor relations section of the Company's website at [investors.tactilemedical.com](http://investors.tactilemedical.com).

For those unable to participate, a replay of the call will be available for two weeks at 800-585-8367 (416-621-4642 for international callers); access code 9563758. The webcast will be archived at [investors.tactilemedical.com](http://investors.tactilemedical.com).

### **About Tactile Medical**

Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency. Tactile Medical's Mission is to help people suffering from chronic diseases live better and care for themselves at home. The Company's unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinicians. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.

### Investor Inquiries:

Mike Piccinino, CFA  
Managing Director  
Westwicke Partners  
443-213-0500  
[investorrelations@tactilemedical.com](mailto:investorrelations@tactilemedical.com)



Source: Tactile Systems Technology, Inc.